Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia.

F Grignani

    Critical Reviews in Oncology/Hematology
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Chronic myelocytic leukemia (CML) is a myeloproliferative disorder that transforms into a lethal blastic crisis. Research advances understanding of CML, but treatment progress remains limited, necessitating focus on prognostic factors and future therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    PML is required for telomere stability in non-neoplastic human cells.

    Oncogene·2016
    Same author

    PML is required for telomere stability in non-neoplastic human cells.

    Oncogene·2015
    Same author

    Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors.

    Cell death and differentiation·2013
    Same author

    deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation.

    Cell death and differentiation·2007
    Same author

    PML/RAR alpha fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype.

    Blood·2000
    Same author

    Gene regulation in normal and leukaemic progenitor/stem cells.

    Haematologica·2000
    Same journal

    Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

    Critical reviews in oncology/hematology·2026
    Same journal

    Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

    Critical reviews in oncology/hematology·2026
    Same journal

    Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

    Critical reviews in oncology/hematology·2026
    Same journal

    DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

    Critical reviews in oncology/hematology·2026
    Same journal

    Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

    Critical reviews in oncology/hematology·2026
    Same journal

    Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

    Critical reviews in oncology/hematology·2026
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Molecular Biology

    Background:

    • Chronic myelocytic leukemia (CML) is a myeloproliferative neoplasm with characteristic clinical and hematological features.
    • CML typically progresses to a fatal blastic crisis within approximately 4 years if untreated.
    • Recent advancements have improved understanding of CML's cellular and molecular underpinnings.

    Purpose of the Study:

    • To review current knowledge regarding the cellular, chromosomal, biochemical, and immunological aspects of chronic myelocytic leukemia.
    • To assess the limited progress in polychemotherapy for CML treatment.
    • To highlight the importance of prognostic factors and emerging therapeutic strategies.

    Main Methods:

    • Review of existing literature on chronic myelocytic leukemia.

    Related Experiment Videos

  • Analysis of chromosomal abnormalities, cellular behavior, and immunological markers in CML.
  • Evaluation of treatment outcomes and prognostic indicators.

    • Main Results:

    • Significant progress has been made in understanding the leukemic cells, chromosomal abnormalities, and immunology of CML.
    • Polychemotherapy has shown limited efficacy in improving CML treatment outcomes.
    • Prognostic factor research offers a more rational treatment approach.

    Conclusions:

    • Further insights into CML pathogenesis are expected from monoclonal antibody techniques.
    • Bone marrow transplantation holds promise for future CML treatment.
    • A better understanding of prognostic factors is crucial for optimizing CML management.